Prospective multicenter trial shows improved progression-free survival in mantle cell lymphoma with zanubrutinib post-ASCT, indicating favorable safety.
Key Points
To investigate the safety and efficacy of zanubrutinib maintenance therapy following autologous stem cell transplantation in mantle cell lymphoma patients.
Phase II multicenter trial conducted in five centers in China.
Enrolled patients aged 18-65 with confirmed stage III/IV mantle cell lymphoma eligible for ASCT.
Participants received oral zanubrutinib for 2 years post-transplant; primary endpoint was event-free survival.
All 13 patients on zanubrutinib maintenance were alive after a median follow-up of 1017 days.
The 3-year progression-free survival was 100% in the zanubrutinib group compared to 62.5% in controls.
Zanubrutinib maintenance was well-tolerated with no serious adverse events leading to treatment discontinuation.